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Abstract
Objectives
This study was conducted to examine the development and molecular mechanisms of amphenicol resistance
in Campylobacter jejuni by using in vitro selection with chloramphenicol and florfenicol. The impact of the
resistance development on growth rates was also determined using in vitro culture.
Methods
Chloramphenicol and florfenicol were used as selection agents to perform in vitro stepwise selection. Mutants
resistant to the selective agents were obtained from the selection process. The mutant strains were compared
with the parent strain for changes in MICs and growth rates. The 23S rRNA gene and the L4 and L22
ribosomal protein genes in the mutant strains and the parent strain were amplified and sequenced to identify
potential resistance-associated mutations.
Results
C. jejuni strains that were highly resistant to chloramphenicol and florfenicol were obtained from in vitro
selection. A novel G2073A mutation in all three copies of the 23S rRNA gene was identified in all the resistant
mutants examined, which showed resistance to both chloramphenicol and florfenicol. In addition, all the
mutants selected by chloramphenicol also exhibited the G74D modification in ribosomal protein L4, which
was previously shown to confer a low-level erythromycin resistance in Campylobacter species. The mutants
selected by florfenicol did not have the G74D mutation in L4. Notably, the amphenicol-resistant mutants also
exhibited reduced susceptibility to erythromycin, suggesting that the selection resulted in cross resistance to
macrolides.
Conclusions
This study identifies a novel point mutation (G2073A) in 23S rRNA in amphenicol-selected mutants of C.
jejuni. Development of amphenicol resistance in Campylobacter likely incurs a fitness cost as the mutant
strains showed slower growth rates in antibiotic-free media.
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Objectives: This study was conducted to examine the development and molecular mechanisms of amphenicol resistance in
Campylobacter jejuni by using in vitro selection with chloramphenicol and florfenicol. The impact of the resistance
development on growth rates was also determined using in vitro culture.
Methods: Chloramphenicol and florfenicol were used as selection agents to perform in vitro stepwise selection. Mutants
resistant to the selective agents were obtained from the selection process. The mutant strains were compared with the
parent strain for changes in MICs and growth rates. The 23S rRNA gene and the L4 and L22 ribosomal protein genes in the
mutant strains and the parent strain were amplified and sequenced to identify potential resistance-associated mutations.
Results: C. jejuni strains that were highly resistant to chloramphenicol and florfenicol were obtained from in vitro selection.
A novel G2073A mutation in all three copies of the 23S rRNA gene was identified in all the resistant mutants examined,
which showed resistance to both chloramphenicol and florfenicol. In addition, all the mutants selected by chloramphenicol
also exhibited the G74D modification in ribosomal protein L4, which was previously shown to confer a low-level
erythromycin resistance in Campylobacter species. The mutants selected by florfenicol did not have the G74D mutation in
L4. Notably, the amphenicol-resistant mutants also exhibited reduced susceptibility to erythromycin, suggesting that the
selection resulted in cross resistance to macrolides.
Conclusions: This study identifies a novel point mutation (G2073A) in 23S rRNA in amphenicol-selected mutants of C. jejuni.
Development of amphenicol resistance in Campylobacter likely incurs a fitness cost as the mutant strains showed slower
growth rates in antibiotic-free media.
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Introduction
Campylobacter jejuni is a leading bacterial cause of acute
gastroenteritis in humans [1]. Campylobacter infection is also the
most common antecedent to Guillain-Barre´ syndrome (GBS),
manifested as symmetric ascending paralysis [2,3]. Usually,
Campylobacter infections are self-limiting; however, clinical antimi-
crobial treatment is warranted in patients with severe or long-
lasting infections, or with compromised immune systems [4,5].
However, antimicrobial resistance in C. jejuni has increased
significantly over the past decades, compromising clinical treat-
ments and presenting a major public health threat [6–9].
Chloramphenicol (CHL) and florfenicol (FFC) are members of
the amphenicol family, which are highly effective against a wide
variety of Gram-positive and Gram-negative bacteria. Ampheni-
cols were once widely applied in both human and veterinary
practice for the prevention and treatment of many bacterial
infections. Florfenicol, the fluorinated derivative of chloramphen-
icol, has been licensed for the control of bacterial respiratory tract
infections in several food production animals, including cattle and
pigs [10]. Nowadays, the use of chloramphenicol is limited to a
small number of life-threatening infections in humans because of
its adverse effects, which include bone-marrow depression, aplastic
anaemia, and acute leukaemia [11–13]. The use of chloramphen-
icol in food-producing animals was banned in many countries;
however, it is still widely used in pets and non-food-producing
animals [14–16]. Chloramphenicol binds directly to the peptidyl-
transferase centre on the 50S ribosomal subunit, preventing
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peptide bond formation [17]. Acetylation of the drug by
chloramphenicol acetyltransferase, which does not mediate
resistance to FFC, is the most frequently encountered mechanism
of bacteria resistance to CHL [10]. Other mechanisms of CHL
resistance include efflux systems such as cmlA [18], floR [19], fexA
[20], fexB [21], pexA [22]; point mutations in domain V of the 23S
rRNA [23]; and methylation of A2503 in the 23S rRNA gene of
the large ribosomal subunit, which is catalysed by cfr methyltrans-
ferase [24].
A series of studies showed that CHL resistance was very
common in E. coli (40.6–79%) [25,26] and Salmonella (28.42%)
[27], while chloramphenicol resistance in Campylobacter rarely
occurs. No chloramphenicol-resistant isolates were detected in
studies performed in the United States [28], Spain [29], Japan
[30], and Iran [31]. The chloramphenicol resistance detection
rates were 0.8% in Korea [32]. In contrast to the low resistance
rates in other countries, detection of chloramphenicol-resistant
Campylobacter was high (37.5%) in Brazil [33]. In China, the
florfenicol and chloramphenicol resistance rates of Campylobacter
isolated from chicken [34] reached up to 61.7 and 24.5%,
respectively. Chloramphenicol resistance in Campylobacter is medi-
ated by chloramphenicol acetyltransferases [35–37]. To date,
there have been no reports on FFC resistance mechanisms in
Campylobacter. In this study, we examined the development of CHL
and FFC resistance mechanisms in C. jejuni by in vitro selection and
assessed the impact of the resistance on Campylobacter fitness.
Materials and Methods
Bacterial strains and culture conditions
The C. jejuni strain ATCC 33560, susceptible to CHL and FFC
(MICCHL= 4 mg/mL and MICFFC= 2 mg/mL), was used as the
parent strain for the selection studies with CHL and FFC. C. jejuni
was cultured routinely on Mueller-Hinton agar (MHA, Sigma, St.
Louis, MO) or in Mueller-Hinton broth (MHB, Sigma) for 24–48
hours at 42uC under microaerobic conditions (5% O2, 10% CO2,
and 85% N2). If necessary, the MH media were supplemented
with various concentrations of CHL or FFC. All strains were
preserved in MH broth with 20% glycerol at 280uC.
CHL & FFC susceptibility testing
The MICs against CHL and FFC were determined using the
agar dilution method as recommended by the Clinical and
Laboratory Standards Institute [38]. According to the recom-
mended breakpoints of NARMS [39], isolates were considered
resistant to CHL and FFC if their MICs were $32 and $8 mg/
mL, respectively. CHL, FFC, erythromycin, azithromycin, spira-
mycin, and clindamycin were purchased from the China Institute
of Veterinary Drug Control, Beijing. Phenylalanine-arginine-b-
naphthylamide (PAbN, Sigma-Aldrich, St. Louis, MO), an efflux
pump inhibitor, was also used in this study to identify whether the
antibiotic efflux systems of C. jejuni played a role in the resistance.
The concentration of PAbN used in this study was 30 mg/mL [40].
A control plate of MH agar containing PAbN of the same
concentration was also included to assess the effect of PAbN on the
growth of the isolates investigated. The experiments mentioned
above were repeated three times.
In vitro selection of CHL and FFC resistant strains
CHL- and FFC-resistant strains were selected in vitro with CHL
and FFC as the selective agents, respectively. Briefly, the parent
strain ATCC 33560 was first cultured on antimicrobial-free MHA
media. For first round of selection, cultures of the parent strain
were inoculated onto MHA media containing CHL or FFC at 0.5-
fold MICs, and incubated under microaerobic conditions at 42uC
for 3–5 days. For subsequent stepwise selection, cultures were
collected and transferred to MHA containing a 2-fold higher
concentration of antibiotics than the concentration used in the
preceding round of selection. The highest concentrations of
selective agents are 16-fold and 64-fold MIC for CHL and FFC,
respectively. Single colonies (n = 10) were picked and tested at
each stepwise selection. MICs of resistant clones against CHL and
FFC and erythromycin, azithromycin, spiramycin, and clindamy-
cin were determined accordingly.
Growth rates of the parent and mutant strains in MH
broth
To compare the growth kinetics of selected resistant strains (C3
and F5) with the susceptible parent strain, a fresh culture of each
strain was separately and equally inoculated into antimicrobial-
free MH broth at an initial cell density of OD600 = 0.05. The
cultures were incubated at 42uC under microaerobic conditions,
and then aliquots of the samples were collected at 0, 4, 8, 12, 24,
and 36 hours post-inoculation for OD600 determination. Three
independent experiments were performed.
Sequence analysis of genes encoding 23S rRNA, L4
ribosomal protein, and L22 ribosomal protein
With respect to the 23S rRNA gene, we used the specific primer
pair 23S-F and 23S-R to amplify all three copies of the 23S rRNA
gene to detect potential CHL or FFC resistance-associated
mutations (Table 1). To detect which specific copy of the gene
contained the mutation, PCRs were performed to amplify each
copy of the domain V of 23S rRNA gene. The three pairs of
operon-specific PCR primers (FI/CJ copy-R; FII/CJ copy-R; and
FIII/CJ copy-R) are listed in Table 1 [41]. The amplification
reactions were performed with premixed LA Taq (TaKaRa Co.
Ltd., Dalian, China), and the cycling parameters were 95uC for
5 min, followed by 30 cycles of 95uC for 30 sec for denaturation,
55uC for 30 sec for annealing, and 68uC for 5 min for extension.
The PCR cycles were followed by a final extension period of
15 min at 68uC. The PCR products were purified by using
TIANGEN DNA midi purification kit (TIANGEN, Beijing,
China) and subsequently sequenced.
The sequences of the L4 and L22 ribosomal protein genes from
the resistant clones were analysed in comparison with the parental
strain using primers as previously described [42]. The PCR cycling
conditions for the L4 and L22 genes were as follows: initial
denaturation at 95uC for 5 min, followed by 30 cycles of 95uC for
30 sec, 55uC for 30 sec, 72uC for 45 sec, with a final extension at
72uC for 5 min. The PCR products were purified and sequenced
for point mutations.
Results
Development of CHL and FFC resistance in C. jejuni by in
vitro selection
Through independent stepwise in vitro selection experiments
with CHL or FFC as the selective agents, we acquired C. jejuni
strains of different resistance levels to the antibiotics. The selected
resistant strains are listed in Table 2. Three successive generations
of CHL-resistant strains (MICC1= 32 mg/mL; MICC2= 64 mg/
mL; and MICC3= 128 mg/mL) and five successive generations of
FFC-resistant strains (MICF1= 16 mg/mL; MICF2= 32 mg/mL;
MICF3 = 64 mg/mL; MICF4= 128 mg/mL; and MICF5= 256 mg/
mL) were chosen for further analysis. MICs of these strains were
determined with or without PAbN in comparison with the parent
Amphenicol Resistance in C. jejuni
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strain ATCC 33560. As shown in Table 2, the selected mutants
showed $8-fold increases in the MICs of CHL and FFC
compared to ATCC33560. Addition of PAbN in the assay made
little differences in the MICs (no change or 2-fold decrease;
Table 2), and the PAbN alone did not affect the growth of the
isolates investigated. As shown in Table 2, all CHL-resistant
strains and high-level FFC-resistant strains (including F3, F4, and
F5) showed decreased susceptibility to the both selective agents.
Interestingly, the MICs of erythromycin against mutant strains C3
and F5 increased eight-fold (from 1 to 8 mg/mL), and the MICs of
azithromycin increased four-fold (from 0.25 to 1 mg/mL), but were
still lower than the resistance breakpoints ($16 and $8 mg/mL,
respectively), suggesting that selection with amphenicol led to a
low-level cross-resistance to macrolides. However, the MICs of
spiramycin and clindamycin only increased two-fold (data not
shown).
Molecular mechanism of Chloramphenicol and
Florfenicol resistance
i) Analysis of domain V of the 23S rRNA gene
PCRs were performed with specific primers 23S-F and 23S-R
(Table 1) to identify the potential mutations in domain V of
the 23S rRNA gene in the selected resistant C. jejuni strains.
Sequence analysis showed that a G-to-A single nucleotide
change was detected at position 2073 of 23S rRNA
(corresponding to position 2057 in the 23S rRNA gene of
Escherichia coli) of all the mutants examined (Table 2). Further
studies were performed with operon-specific primer pairs (FI/
Cj copy R, FII/Cj copy R, and FIII/Cj copy R) to amplify
and analyse the three copies of the 23S rRNA gene in the
mutant strain. The results indicated that these mutants
exhibited the G2073A mutation in all three copies of the
gene (Table 2). When analysing the process of resistance
development, we did not found the mutation in any of the
three copies of the 23S rRNA gene in the FFC-selected clones
with MICFFC #16 mg/mL and the CHL-selected clones with
MICCHL #32 mg/mL.
ii) Sequence analysis of L4 and L22 ribosomal protein genes
The selected mutant strains and the parent strain were
examined for alterations in the L4 and L22 ribosomal protein
genes. The G74D change, which was previously reported to
confer low-level resistance to erythromycin in Campylobacter
[42–44], was detected in the L4 protein in all the CHL-
selected mutants (MICCHL$16 mg/mL), but was absent in the
FFC-selected strains, regardless of the resistance levels FFC
(Table 2). No mutations were detected in the L22 ribosomal
protein gene in either CHL-selected or FFC-selected mutants
(Table 2).
Growth kinetics of the resistant strains
Two mutant strains (C3 and F5) and the parent strain were
separately inoculated into antimicrobial-free MH broth and tested
for growth rates. For the first 8 hours of incubation post-
inoculation, the two mutant strains showed little growth
(Figure 1). According to the OD values, the C3 and F5 strains
showed apparent differences in growth kinetics between the wild-
type parent strain and the mutants, suggesting that the C3 and F5
mutants might have impaired fitness.
Discussion
C. jejuni has become increasingly resistant to antimicrobials,
which poses a significant threat to human health. There were
numerous studies on antimicrobial resistance of Campylobacter
species [45-47], but very few focused on the mechanism of CHL
and FFC resistance [36]. In this study, C. jejuni strain ATCC
33560, which usually serves as a quality-control strain for the
antimicrobial susceptibility testing of Campylobacter spp. [38,48],
was used as the parent strain to select for CHL- or FFC-resistant
C. jejuni in vitro [49].
In this study, some unique features were revealed concerning
the development of CHL and FFC resistance in C. jejuni. Firstly,
irrespective of the selective agent, the resistant clones obtained in
vitro exhibited dual resistance to both agents (Table 2). Similar
cross-resistance was previously reported in E. coli and Salmonella
[50,51], which usually emerged under FFC selection. Combined
resistance to CHL and FFC might be conferred by specific
resistance genes, such as floR [19], fexA [20], fexB [21], pexA [22]
and cfr [24]. Secondly, both the CHL- (MICCHL$64 mg/mL) and
FFC-selected (MICFFC$32 mg/mL) resistant strains contained the
G2073A mutation in three copies of the 23S rRNA gene (Table 2),
which is the first reported mutation associated with amphenicol
resistance in Campylobacter spp. The G2057A mutation of the E. coli
23S rRNA gene (corresponding to position 2073 in the 23S rRNA
gene of Campylobacter spp.) was previously reported to confer
Table 1. Primers used in this article.
Primers Sequence (59-39) References
23S-F 59-AGCTACTAAGAGCGAATGGT-39 this study
23S-R 59-AAAGATAAGCCAAACGCTCT-39 this study
FI 59-CCCTAAGTCAAGCCTTTCAATCC-39 [40]
FII 59-CGTTATAGATACGCTTAGCGGTTATG-39 [40]
FIII 59-CATCGAGCAAGAGTTTATGCAAGC-39 [40]
CJ copy-R 59-CTACCCACCAGACATTGTCCCAC-39 [40]
L4-F 59-GTAGTTAAAGGTGCAGTACCA-39 [40]
L4-R 59-GCGAAGTTTGAATAACTACG-39 [40]
L22-F 59-GAATTTGCTCCAACACGC-39 [40]
L22-R 59-ACCATCTTGATTCCCAGTTTC-39 [40]
doi:10.1371/journal.pone.0094503.t001
Amphenicol Resistance in C. jejuni
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resistance to chloramphenicol and intermediate-level resistance to
14-nunbered-ring macrolides. Indeed, the CHL- and FFC-selected
C. jejuni mutants carrying the G2073A mutation also showed
elevated MICs to erythromycin (8 mg/mL), consistent with the
finding in E. coli that the G2057A conferred cross resistance to
chloramphenicol and erythromycin [23]. Interestingly in propi-
onibacteria [32], Mycoplasma hominis [33], and Francisella tularensis
[31], the same G2057A mutation was associated with erythromy-
cin resistance, but not with resistance to 16-membered macrolides
or chloramphenicol. It was postulated that the G2057 mutation in
the 23S rRNA gene might lead to conformational changes in the
binding sites of CHL and 14-membered macrolides, attenuating
the affinity of these antimicrobials to the ribosome [52].
The G74D modification was found in the L4 ribosomal protein
of CHL-selected resistant strains (MICCHL$16 mg/mL), while the
modification was absent in FFC-selected mutants, suggesting that
the structural differences between CHL and FFC might contribute
to the difference in the mutant selection process. FFC is a synthetic
derivative of CHL with a fluoro group substitution at position C3
and the replacement of a nitro group (-NO2) by a sulfomethyl
group (-SO2CH3) [53]. It is also possible that there are differences
in the binding sites for CHL and FFC in ribosomal protein L4, or
differences in the mode of action between CHL and FFC. The
G74D mutation is located in a conserved region of the L4
ribosomal protein, which is considered as the main anchoring site
of this ribosomal protein to 23S rRNA [54]. Several previous
reports also identified the G74D mutation in ribosomal protein L4
of Campylobacter spp. [33,42,55], and this mutation, by itself, usually
conferred low-level resistance to erythromycin and contributed to
higher-level resistance when combined with the efflux pump
CmeABC [56] or a G57V mutation in L4 [43]. Furthermore, the
result from the PAbN assay suggested that the efflux mechanism
might not play a major role in resistance to CHL and FFC in the
mutant strains that carried the G2073A mutation. Thus, the
G2073A rRNA mutation alone may be sufficient to confer
resistance to CHL and FFC in C. jejuni mutants. It was reported in
E. coli that the G2057A change in combination with other
mutations in the 23S rRNA gene (i.e., G2032A) conferred a higher
level of chloramphenicol resistance [57].
Several studies investigated the fitness of antibiotic-resistant
Campylobacter spp. with mutation-associated resistance [58–60]. In
the study of Luo et al. [58], they reported that fluoroquinolone-
resistant Campylobacter showed an enhanced fitness in vivo.
However, macrolide-resistant Campylobacter demonstrated a severe
defect in both in vitro and in vivo fitness [60]. These finding indicate
that different target mutations have varied impact on Campylobacter
fitness. The results from the growth experiment in this study
(Figure 1) demonstrated that the G2073A alteration in the 23S
rRNA gene had a negative effect on the growth rates of the mutant
strains, which suggests that development of amphenicol resistance
incurs a fitness cost in Campylobacter. It appeared that the CHL-
selected strains exhibited the most significant fitness disadvantage
(Figure 1).
In conclusion, we discovered a novel G2073A mutation in the
23S rRNA gene of C. jejuni that is associated with amphenicol
resistance. This mutation was identified by in vitro selection using
CHL or FFC. Notably, this G2073A mutation was also associated
with reduced susceptibility to erythromicin, suggesting that it
confers cross resistance to both amphenicols and macrolides.
Considering that the amphenicol resistance rates in Campylobacter
are rising in certain countries, it will be interesting to determine if
this resistance-associated mutation is naturally present in clinical
isolates and if the amphenicol-resistant mutants are able to
continue to persist in the absence of antibiotic selection pressure.
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Figure 1. Growth kinetics of the wild-type strain and mutant strains of C. jejuni in MH broth. The OD600 were measured at 0, 4, 8, 12, 24
and 36 hours post-inoculation. Two mutant strains (C3 and F5) and the parent strain ATCC 33560 were included in the experiment. The experiment
was repeated three times, and the results were shown as mean of three independent experiments.
doi:10.1371/journal.pone.0094503.g001
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